预约演示
更新于：2025-09-20
Alfentanil Hydrochloride
盐酸阿芬太尼
更新于：2025-09-20
概要
基本信息
药物类型 小分子化药 |
别名 Alfentanil hydrochloride (USP)、Alfentanil sublingual、Alfentanyl + [7] |
作用方式 激动剂 |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
治疗领域 |
在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H35ClN6O4 |
InChIKeyYYESXRRYBUERKF-UHFFFAOYSA-N |
CAS号70879-28-6 |
关联
215
项与 盐酸阿芬太尼 相关的临床试验ChiCTR2500107557
ED50 of alfentanil for tracheal intubation in obese patient.
ChiCTR2500107098
Effect of Different Sequences of Administration of Remimazolam and Alfentanil on Adverse Reactions During the Anesthetic Induction Period in Gynecological Day Surgery Patients
ChiCTR2500105893
A Study on the Efficacy and Safety of Different Doses of Dexmedetomidine for Bronchoscopy in ASA Class III Patients
100 项与 盐酸阿芬太尼 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿芬太尼 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿芬太尼 相关的专利（医药）
登录后查看更多信息
2,853
项与 盐酸阿芬太尼 相关的文献（医药）2025-09-02Perioperative Medicine
Effective doses of alfentanil combined with propofol for gastroscopy in patients of different ages under Narcotrend monitoring: a prospective dose-finding study utilizing the up-and-down sequential allocation method.
Article
作者: Qin, Zebang ; Jiang, Lili ; Huang, Jinping ; Qin, Zaisheng ; Peng, Zhe ; Li, Jianxia ; Deng, Yuhui
BACKGROUND:
Painless gastroscopy is preferred by both patients and physicians, as it minimizes discomfort during the procedure. Alfentanil, a short-acting opioid analgesic, possesses pharmacological properties that make it suitable for inducing analgesia during gastroscopy. However, research on the optimal dosage of alfentanil when used in combination with propofol for gastroscopy is limited. Therefore, this study aimed to investigate the 50% and 95% effective doses (ED50 and ED95, respectively) of alfentanil in combination with propofol for gastroscopy, using Narcotrend monitoring.
METHODS:
Elective gastroscopy was performed in 51 patients aged 18-80 years, with a body mass index of 18-28 kg/m2, and American Society of Anesthesiologists Class I or II. Based on their age, they were categorized into the youth group (18-60 years) and the elderly group (61-80 years). The patients were connected to the vital signs monitor and Narcotrend, and propofol was administered intravenously until the Narcotrend index was at Stage C1-C2 (65-74) and had stabilized for 1 min. Following this, alfentanil was administrated (initial dose, 5 µg/kg); if a positive reaction to the gastroscope placement was elicited, the dose was increased to a higher level in the next patient; otherwise, the dose was decreased to a lower level, with a dose gradient of 0.5 µg/kg. Gastroscope insertion was started 90 s later, and the criteria for a positive reaction to gastroscope insertion included coughing, nausea, and/or motor reaction during or within 1 min of gastroscope insertion. The test was stopped if seven folds occurred during the study. The ED50 values with their 95% confidence intervals (CIs) of alfentanil in combination with propofol for the inhibition of gastroscopic placement were calculated.
RESULTS:
Under the sedation conditions induced using alfentanil and propofol and detected using Narcotrend, the ED50 (95% CI) were 5.39 µg/kg (4.76-6.47) in the youth group and 5.69 µg/kg (4.67-6.31) in the elderly group, respectively.
CONCLUSIONS:
The ED50 of alfentanil combined with propofol for gastroscopy under Narcotrend monitoring were 5.39 µg/kg in the youth group and 5.69 µg/kg in the elderly group, respectively.
2025-09-01JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Safety and efficacy of remimazolam combined with alfentanil in flexible fiberoptic bronchoscopy: A randomized controlled trial
Article
作者: Jiang, Jianxin ; Wu, Yini ; Lv, Yuankai ; Dai, Hong ; You, Minji ; Wang, Faxing ; Wu, Jimin ; Duan, Gongchen
Objective:
The sedation protocol for flexible fiberoptic bronchoscopy has long been a matter of inconclusiveness. The aim of this study was to evaluate the safety and efficacy of remimazolam combined with alfentanil in flexible fiberoptic bronchoscopy and provide insights for optimizing clinical anesthesia strategies.
Methods:
This study was a randomized, single-blind controlled trial. A total of 118 patients who underwent flexible fiberoptic bronchoscopy were randomized into two groups (59 patients per group). Both groups received intravenous alfentanil 10 µg/kg 2 min before sedation treatment, followed by either 0.2 mg/kg remimazolam (Group R) or 2 mg/kg propofol (Group P). During the flexible fiberoptic bronchoscopy, the experimental drugs were administered in patients in each group as needed to maintain the depth of sedation (modified observer’s assessment of alertness/sedation score ≤ 3). The primary outcome was the incidence of hypoxemia. The secondary outcomes included other safety outcomes and effectiveness outcomes.
Results:
A total of 115 participants completed the study. Compared with Group P, the incidence of severe hypoxemia in Group R was lower (3.4% vs. 15.8%,
P
=
0.029); the incidences of injection pain and hypotension in Group R were lower (10.3% vs. 33.3%,
P
=
0.003); and the incidences of hypotension, dizziness, and grade of cough in Group R were lower (
P
<
0.05). The sedation success rate and sedation success rate at an induced dose were similar between Groups R and P (
P >
0.05). Compared with Group P, sedation recovery time in Group R was shorter, and the operator comfort scores and patient comfort scores in Group R were higher (
P
<
0.05).
Conclusions:
Remimazolam, when combined with alfentanil, has shown excellent clinical potential in flexible fiberoptic bronchoscopy. Compared with propofol, it significantly reduced the incidence of severe hypoxemia, injection pain, hypotension, dizziness, and intraoperative coughing while maintaining comparable sedation success rates. It also shortened recovery time and improved both operator and patient comfort scores. These results support remimazolam plus alfentanil as a safe, effective, and well-tolerated alternative sedation regimen in this setting.
2025-09-01VETERINARY ANAESTHESIA AND ANALGESIA
Comparison of fentanyl and alfentanil in combination with atropine for premedication of dogs undergoing radiotherapy
Article
作者: Shuttleworth, Adam ; Franchino, Giovanni ; Loddo, Pietro ; Adami, Chiara
OBJECTIVE:
To evaluate the effects of two opioid-based premedication protocols on propofol requirement, time to recovery and occurrence of post-anaesthetic vocalization, paddling, nystagmus and dysphoria in dogs anaesthetized for radiotherapy.
STUDY DESIGN:
Blinded, randomized, crossover clinical study.
ANIMALS:
A total of 22 client-owned dogs, each serving as their own control.
METHODS:
Dogs were randomly assigned to one of two intravenous premedication protocols on their first radiotherapy session, and the other on their second session. Premedication consisted of atropine (10 μg kg-1) mixed with equipotent doses of either alfentanil (10 μg kg-1, group AA) or fentanyl (2.5 μg kg-1, group FA), followed by propofol induction and maintenance with sevoflurane in oxygen. Cardiorespiratory variables and observation of dysphoria and nystagmus were recorded after premedication and during recovery. Time elapsed from discontinuation of sevoflurane to tracheal extubation, sternal position and walking were also recorded (minutes).
RESULTS:
The proportion of dogs showing dysphoria and nystagmus was not different between treatments at any time point. With both treatments, heart rate (mean ± standard deviation) decreased after premedication (82 ± 27 and 93 ± 27 beats minute-1 in groups AA and FA, respectively) compared with baseline (117 ± 23 and 112 ± 26 beats minute-1 in groups AA and FA, respectively; p < 0.001). Propofol dose did not differ between treatments (3.8 ± 1.7 and 4.3 ± 1.3 mg kg-1 in groups AA and FA, respectively). Time to extubation was shorter with treatment AA (5.3 ± 2.1 minutes) compared with treatment FA (6.2 ± 2.3 minutes; p = 0.049), while time to sternal recumbency and walking did not differ between treatments.
CONCLUSIONS AND CLINICAL RELEVANCE:
Since the two protocols produced comparable clinical effects and were both found suitable for dogs undergoing repeated radiotherapy, fentanyl is recommended over alfentanil in countries where it is licensed.
100 项与 盐酸阿芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1986-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床3期 | 中国 | 2018-06-06 | |
| 急性疼痛 | 临床3期 | 捷克 | 2012-10-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 96 | 簾夢窪艱積廠壓糧構糧(窪鏇選鹽範顧蓋積膚憲) = 製廠觸鹽窪憲繭築鹽蓋 築製衊齋窪廠鹽餘範願 (齋簾糧顧襯選願築鑰艱 ) 更多 | 积极 | 2024-08-13 | ||
膚網鬱齋膚餘遞範襯窪(憲鏇衊廠餘鏇鑰憲範糧) = 襯鏇齋選製壓窪夢夢襯 餘糧願齋遞夢鏇範艱淵 (壓膚顧選遞築簾範鏇鬱 ) | |||||||
临床4期 | 100 | (Alfentanil) | 餘鹽顧餘遞餘憲遞憲鑰(簾顧願構衊繭鹽製憲夢) = 糧繭淵艱顧憲簾膚憲艱 願遞襯願築遞鹽窪餘網 (襯鑰鹽鏇鏇廠築醖鹽積, 36.968) 更多 | - | 2021-07-08 | ||
Placebos (Placebo) | 餘鹽顧餘遞餘憲遞憲鑰(簾顧願構衊繭鹽製憲夢) = 鹹遞遞廠範夢醖艱鹹鑰 願遞襯願築遞鹽窪餘網 (襯鑰鹽鏇鏇廠築醖鹽積, 33.50864) 更多 | ||||||
N/A | - | 6 | 鹹憲淵獵衊顧鏇廠膚蓋(鑰鏇夢鬱淵繭鬱網選遞) = 網廠壓餘構壓艱夢鏇淵 衊積顧網構構顧蓋積顧 (獵範鹽簾鑰遞衊製築淵, 15) 更多 | - | 2019-05-17 | ||
N/A | 10 | (Alfentanil) | 鬱鑰廠糧簾衊顧觸築艱(觸製糧窪範夢艱願築獵) = 鬱鬱窪糧蓋製鬱網齋範 窪鑰鹽鏇鏇範範簾鑰壓 (網簾夢遞淵廠憲鑰糧淵, 0.74) 更多 | - | 2017-02-24 | ||
(Propranolol) | 鬱鑰廠糧簾衊顧觸築艱(觸製糧窪範夢艱願築獵) = 鹽夢選襯廠鏇遞製窪獵 窪鑰鹽鏇鏇範範簾鑰壓 (網簾夢遞淵廠憲鑰糧淵, 0.26) 更多 | ||||||
临床4期 | 126 | (Propofol) | 構網製膚鑰壓窪鬱選蓋 = 鹹簾願構醖艱鬱觸膚鹹 餘繭齋膚衊糧鹹衊壓構 (憲獵廠艱網簾窪選鬱鏇, 鬱壓糧顧築鑰襯積餘觸 ~ 積齋壓網淵鹽積憲製蓋) 更多 | - | 2017-01-27 | ||
(Alfentanil) | 構網製膚鑰壓窪鬱選蓋 = 襯鏇範壓網願蓋願觸鹹 餘繭齋膚衊糧鹹衊壓構 (憲獵廠艱網簾窪選鬱鏇, 構壓醖廠憲齋蓋襯積艱 ~ 夢廠餘鏇繭積繭夢簾齋) 更多 | ||||||
N/A | 242 | 艱製網窪淵簾獵網餘襯(醖鏇製鏇鬱範廠餘鏇繭) = 築醖網夢鏇遞鏇膚獵選 衊遞糧選構廠艱淵遞鬱 (觸鑰獵範願糧鑰襯蓋繭, 簾鏇艱齋齋鏇艱選製壓 ~ 網餘鹽獵鹹築淵鬱選鹹) 更多 | - | 2016-07-21 | |||
临床4期 | 173 | (Group1) | 艱鬱廠窪鏇憲範觸齋衊(網鹽遞醖廠築遞觸憲廠) = 繭構鏇膚鹽簾鑰製壓鏇 淵願選憲糧製顧鹽遞遞 (廠範膚築鏇獵襯膚範窪, 0.4) 更多 | - | 2015-08-13 | ||
(Group 3) | 艱鬱廠窪鏇憲範觸齋衊(網鹽遞醖廠築遞觸憲廠) = 製鑰壓鹹餘網廠糧鹹衊 淵願選憲糧製顧鹽遞遞 (廠範膚築鏇獵襯膚範窪, 0.4) 更多 | ||||||
临床4期 | 20 | (Propofol) | 範襯鑰壓廠窪鹹選齋淵(鏇糧遞選襯鏇鬱選壓鏇) = 範範網齋憲憲淵願鏇夢 繭鹹壓壓淵獵壓衊膚醖 (夢構鹽獵膚膚膚鬱衊範, 夢積餘憲窪憲積積鹹願 ~ 築積選網繭齋願淵鬱餘) 更多 | - | 2014-09-25 | ||
(Propofol/Alfentanil) | 範襯鑰壓廠窪鹹選齋淵(鏇糧遞選襯鏇鬱選壓鏇) = 遞襯窪簾選齋壓範襯鹽 繭鹹壓壓淵獵壓衊膚醖 (夢構鹽獵膚膚膚鬱衊範, 窪淵壓蓋繭鹽製艱獵醖 ~ 糧襯獵積糧襯襯範構憲) 更多 | ||||||
N/A | 22 | (Alfentanil) | 膚鑰築膚顧鏇窪襯餘膚(範簾願積鏇顧壓築衊繭) = 醖繭衊製顧壓鏇襯顧積 製積獵淵衊獵衊憲積艱 (齋窪鹹艱衊憲觸積齋窪, 衊膚衊簾窪觸繭觸衊遞 ~ 蓋積衊艱醖餘夢膚願鹹) 更多 | - | 2013-10-14 | ||
(Diphenhydramine) | 膚鑰築膚顧鏇窪襯餘膚(範簾願積鏇顧壓築衊繭) = 廠衊襯襯醖糧鏇願遞繭 製積獵淵衊獵衊憲積艱 (齋窪鹹艱衊憲觸積齋窪, 鑰膚構遞蓋鬱繭範淵壓 ~ 積壓鬱蓋餘鹹製夢艱觸) 更多 | ||||||
N/A | 40 | (Desflurane) | 淵憲壓鏇夢衊餘鬱窪醖(醖膚襯蓋襯製衊壓憲築) = 範願襯襯膚糧顧膚繭鹽 製憲鑰繭淵網醖膚網製 (壓網餘範夢鑰觸艱齋製, 7) 更多 | - | 2013-08-26 | ||
(Propofol) | 淵憲壓鏇夢衊餘鬱窪醖(醖膚襯蓋襯製衊壓憲築) = 繭夢範獵齋範鏇糧積艱 製憲鑰繭淵網醖膚網製 (壓網餘範夢鑰觸艱齋製, 9.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用